ElaineMMajerusMDPhD

Hematology • Saint Louis, MO

Clotting Disorder, Hemophilia & Bleeding Disorder

Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Majerus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Majerus' full profile

Already have an account?

Office
4921 Parkview Pl
Saint Louis, MO 63110
Phone+1 314-362-7216

Fax+1 314-362-8813
Is this information wrong?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2000 - 2003
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1998 - 2000
Saint Louis University School of MedicineClass of 1998

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 1999 - 2025

Clinical Trials

A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
Completed
Phase 2

Publications & Presentations

PubMed

1 citations
Valoctocogene roxaparvovec gene transfer in participants with HIV.
Margaret V Ragni, Elaine Majerus, Sylvia Fong, Bridget Yates, Stephen Scheeler, Lisa Razon, Hua Yu, Divya B Reddy, Tara M Robinson> ;Blood Advances. 2023 Apr 25
Erratum: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.11...
Joshua J. Field, Elaine M. Majerus, Victor R. Gordeuk> ;Blood Advances. 2017 Oct 24
31 citations
Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease
Joshua J. Field, Elaine M. Majerus, Victor R. Gordeuk, Michel Gowhari, Carolyn Hoppe, Matthew M. Heeney, Maureen Achebe, Alex George, Hillary Chu, Brian Sheehan, Manek...> ;Blood Advances. 2017 Sep 12
27 citations
NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease
Joshua J. Field, Elaine M. Majerus, Kenneth I. Ataga, E. Vichinsky, Robert Schaub, Robert Mashal, David G. Nathan> ;Plos One. 2017 Feb 2
61 citations
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
Deepika Vasudevan, Hideyuki Takeuchi, Sumreet Singh Johar, Elaine M. Majerus, Robert S. Haltiwanger> ;Current Biology. 2015 Feb 2
After the treated mole.
Armin Rashidi, Elaine M. Majerus> ;Blood. 2014 May 1
71 citations
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.
Joshua J. Field, Gene Lin, Maureen Okam, Elaine M. Majerus, Jeffrey R. Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, David ...> ;Blood. 2013 Apr 25
5 citations
Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.
David G. Nathan, Joshua J. Field, Gene Lin, Donna Neuberg, Elaine M. Majerus, Onyinye Onyekwere, Jeffrey R. Keefer, Maureen Okam, Ainsley Ross, Joel Linden> ;Transactions of the American Clinical and Climatological Association. 2012 Jan 1
68 citations
Multi-step binding of ADAMTS-13 to von Willebrand factor
Hendrik B. Feys, Patricia J. Anderson, Karen Vanhoorelbeke, Elaine M. Majerus, J E Sadler> ;Journal of Thrombosis and Haemostasis. 2009 Dec 1
18 citations
ADAMTS13 Bound to Endothelial Cells Exhibits Enhanced Cleavage of von Willebrand Factor
Anthony N. Vomund, Elaine M. Majerus> ;The Journal of Biological Chemistry. 2009 Nov 6
3 citations
Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma.
Patricia J Anderson, David Gailani, Hendrik B Feys, Weiqiang Gao, Elaine M Majerus, Karen Vanhoorelbeke, J Evan Sadler> ;Haematologica. 2007 Oct 1
80 citations
O-Fucosylation is required for ADAMTS13 secretion
Lindsay M. Ricketts, Malgosia Dlugosz, Kelvin B. Luther, Robert S. Haltiwanger, Elaine M. Majerus> ;The Journal of Biological Chemistry. 2007 Jun 8
89 citations
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease
Weiqiang Gao, Patricia J. Anderson, Elaine M. Majerus, Elodee A. Tuley, J. Evan Sadler> ;Proceedings of the National Academy of Sciences of the United States of America. 2006 Dec 12
91 citations
Binding of ADAMTS13 to von Willebrand factor.
Elaine M. Majerus, Patricia J. Anderson, J. Evan Sadler> ;The Journal of Biological Chemistry. 2005 Jun 10
88 citations
Cleavage of the ADAMTS13 propeptide is not required for protease activity.
Elaine M. Majerus, Xinglong Zheng, Elodee A. Tuley, J. Evan Sadler> ;The Journal of Biological Chemistry. 2003 Nov 21
152 citations
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
Xinglong Zheng, Kenji Nishio, Elaine M. Majerus, J. Evan Sadler> ;The Journal of Biological Chemistry. 2003 Aug 8
55 citations
ADAMTS13 and TTP
Xinglong Zheng, Elaine M. Majerus, J. Evan Sadler> ;Current Opinion in Hematology. 2002 Sep 1
628 citations
Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura
Xinglong Zheng, Dominic W. Chung, Thomas K. Takayama, Elaine M. Majerus, J. Evan Sadler, Kazuo Fujikawa> ;The Journal of Biological Chemistry. 2001 Nov 2
Join now to see all